Henry Schein (NASDAQ: HSIC), a distinguished player in the
bio-tech market, recently came to market attention due to various reports ranging from
earnings performance to
analyst ratings. The company's
Q2 earnings outpaced estimates even as the
2024 guidance was reduced. This downgrade is attributed to the fallout of a crippling
cyberattack. Moreover, several
investment firms, including UBS Group, Baird, and Evercore ISI, altered their
price targets, generally lowering the price objective. Several significant names, like GAMMA Investing and Comerica Bank, have substantial stakes in this health care services provider, strengthening their positions. However, the company's stock experienced a gap down to $69.56 following
mixed Q2 results and a cloudy forecast. Going forward, the prospects for Q3 are varied with
analyst predictions indicating a potential decrease in EPS. Nevertheless, Henry Schein remains a popular momentum stock with some analysts advising retaining the stock for long-term benefits, despite the current negative sentiment revolving around its financials.
Henry Schein HSIC News Analytics from Tue, 05 Dec 2023 08:00:00 GMT to Sun, 11 Aug 2024 15:40:52 GMT -
Rating -4
- Innovation -3
- Information 8
- Rumor -5
